Your browser doesn't support javascript.
loading
Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques.
Liang, Frank; Lindgren, Gustaf; Lin, Ang; Thompson, Elizabeth A; Ols, Sebastian; Röhss, Josefine; John, Shinu; Hassett, Kimberly; Yuzhakov, Olga; Bahl, Kapil; Brito, Luis A; Salter, Hugh; Ciaramella, Giuseppe; Loré, Karin.
Affiliation
  • Liang F; Department of Medicine Solna, Immunology and Allergy Unit, L2:04, Karolinska Institutet, 17176 Stockholm, Sweden; Center for Molecular Medicine, Karolinska Institutet, 17176 Stockholm, Sweden.
  • Lindgren G; Department of Medicine Solna, Immunology and Allergy Unit, L2:04, Karolinska Institutet, 17176 Stockholm, Sweden; Center for Molecular Medicine, Karolinska Institutet, 17176 Stockholm, Sweden.
  • Lin A; Department of Medicine Solna, Immunology and Allergy Unit, L2:04, Karolinska Institutet, 17176 Stockholm, Sweden; Center for Molecular Medicine, Karolinska Institutet, 17176 Stockholm, Sweden.
  • Thompson EA; Department of Medicine Solna, Immunology and Allergy Unit, L2:04, Karolinska Institutet, 17176 Stockholm, Sweden; Center for Molecular Medicine, Karolinska Institutet, 17176 Stockholm, Sweden.
  • Ols S; Department of Medicine Solna, Immunology and Allergy Unit, L2:04, Karolinska Institutet, 17176 Stockholm, Sweden; Center for Molecular Medicine, Karolinska Institutet, 17176 Stockholm, Sweden.
  • Röhss J; Department of Laboratory Medicine, Karolinska Institutet, 17177 Stockholm, Sweden; Moderna Therapeutics, 320 Bent Street, Cambridge, MA 02141, USA.
  • John S; Valera LLC, a Moderna Venture, 500 Technology Square, Cambridge, MA 02139, USA.
  • Hassett K; Valera LLC, a Moderna Venture, 500 Technology Square, Cambridge, MA 02139, USA.
  • Yuzhakov O; Valera LLC, a Moderna Venture, 500 Technology Square, Cambridge, MA 02139, USA.
  • Bahl K; Valera LLC, a Moderna Venture, 500 Technology Square, Cambridge, MA 02139, USA.
  • Brito LA; Moderna Therapeutics, 320 Bent Street, Cambridge, MA 02141, USA.
  • Salter H; Moderna Therapeutics, 320 Bent Street, Cambridge, MA 02141, USA; Department of Clinical Neuroscience, Karolinska Institutet, 17177 Stockholm, Sweden.
  • Ciaramella G; Valera LLC, a Moderna Venture, 500 Technology Square, Cambridge, MA 02139, USA.
  • Loré K; Department of Medicine Solna, Immunology and Allergy Unit, L2:04, Karolinska Institutet, 17176 Stockholm, Sweden; Center for Molecular Medicine, Karolinska Institutet, 17176 Stockholm, Sweden. Electronic address: karin.lore@ki.se.
Mol Ther ; 25(12): 2635-2647, 2017 Dec 06.
Article in En | MEDLINE | ID: mdl-28958578
ABSTRACT
mRNA vaccines are rapidly emerging as a powerful platform for infectious diseases because they are well tolerated, immunogenic, and scalable and are built on precise but adaptable antigen design. We show that two immunizations of modified non-replicating mRNA encoding influenza H10 hemagglutinin (HA) and encapsulated in lipid nanoparticles (LNP) induce protective HA inhibition titers and H10-specific CD4+ T cell responses after intramuscular or intradermal delivery in rhesus macaques. Administration of LNP/mRNA induced rapid and local infiltration of neutrophils, monocytes, and dendritic cells (DCs) to the site of administration and the draining lymph nodes (LNs). While these cells efficiently internalized LNP, mainly monocytes and DCs translated the mRNA and upregulated key co-stimulatory receptors (CD80 and CD86). This coincided with upregulation of type I IFN-inducible genes, including MX1 and CXCL10. The innate immune activation was transient and resulted in priming of H10-specific CD4+ T cells exclusively in the vaccine-draining LNs. Collectively, this demonstrates that mRNA-based vaccines induce type-I IFN-polarized innate immunity and, when combined with antigen production by antigen-presenting cells, lead to generation of potent vaccine-specific responses.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: RNA, Messenger / Vaccines / Antigen-Presenting Cells Limits: Animals Language: En Journal: Mol Ther Journal subject: BIOLOGIA MOLECULAR / TERAPEUTICA Year: 2017 Document type: Article Affiliation country: Sweden

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: RNA, Messenger / Vaccines / Antigen-Presenting Cells Limits: Animals Language: En Journal: Mol Ther Journal subject: BIOLOGIA MOLECULAR / TERAPEUTICA Year: 2017 Document type: Article Affiliation country: Sweden